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In human placenta, the ATP-binding cassette efﬂux transporter ABCG2 is highly expressed in syncytio-
trophoblast cells and mediates cellular excretion of various drugs and toxins. Hence, physiological ABCG2
activity substantially contributes to the fetoprotective placenta barrier function during gestation.
Developmental toxicity studies are often performed in rabbit. However, despite its toxicological rele-
vance, there is no data so far on functional ABCG2 expression in this species. Therefore, we cloned ABCG2
from placenta tissues of chinchilla rabbit. Sequencing showed 84e86% amino acid sequence identity to
the orthologues from man, rat and mouse. We transduced the rabbit ABCG2 clone (rbABCG2) in MDCKII
cells and stable rbABCG2 gene and protein expression was shown by RT-PCR and Western blot analysis.
The rbABCG2 efﬂux activity was demonstrated with the Hoechst H33342 assay using the speciﬁc ABCG2
inhibitor Ko143. We further tested the effect of established human ABCG2 (hABCG2) drug substrates
including the antibiotic danoﬂoxacin or the histamine H2-receptor antagonist cimetidine on H33342
accumulation in MDCKII-rbABCG2 or -hABCG2 cells. Human therapeutic plasma concentrations of all
tested drugs caused a comparable competitive inhibition of H33342 excretion in both ABCG2 clones.
Altogether, we ﬁrst showed functional expression of the ABCG2 efﬂux transporter in rabbit placenta.
Moreover, our data suggest a similar drug substrate spectrum of the rabbit and the human ABCG2 efﬂux
transporter.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).-family G member 2; cDNA,
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The placenta serves as a protective barrier by limiting the
transfer of potential toxic xenobiotics from maternal circulation to
the developing fetus. It has recently been suggested that expression
of ATP-binding cassette (ABC) efﬂux transporters in placenta
including ABCG2 makes an important contribution to this protec-
tive mechanism [1]. The 72 kDa half-transporter ABCG2 also
referred to as breast cancer resistance protein (BCRP) shows high
level expression in placenta andwas therefore initially named ABCP
(ABC transporter in placenta) [2]. In the human and murine
placenta barrier, the ABCG2 transport protein is localized at the
apical membrane of syncytiotrophoblast cells, i.e. on the maternal
side [1,3]. The placental ABCG2 mediates cellular excretion of
various drugs and toxins like the antidiabetic drug glyburide, the
antibiotic nitrofurantoin or the dietary pro-carcinogen 2-Amino-1-
methyl-6-phenyl- imidazo[4,5-b]pyridine (PhIP) [4e6]. Hence, the
physiological ABCG2 efﬂux activity limits fetal exposure tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The preferred rodent and non-rodent species for testing of
prenatal developmental toxicity are rat and rabbit, respectively [7].
Compared with rodents which develop a hemotrichorial placenta,
the hemodichorial structure of the rabbit placenta is closer to the
hemomonochorial morphology of human placenta in the last
trimester [8]. Moreover, the placental function of rabbit placenta is
similar to human [8]. This, along with practical consideration, e.g.
about fetus size, made this species a valuable model for human
health hazard assessment. Accordingly, studies on developmental
toxicity in rabbits are preferred over rat studies for biocides
(Regulation (EU) No. 528/2013) or included in legislative data re-
quirements for pesticides (Regulation (EU) No. 283/2013) and other
chemicals. Consequently, 2560 rabbits are used for developmental
toxicity testing in safety evaluations during 2011 in the EU alone
[9]. In spite of the signiﬁcant fetoprotective function of placental
ABCG2 and the regulatory importance of the rabbit in reprotoxicity
studies, no detailed information is as yet available on the active
transport of xenobiotics across the rabbit placenta and the contri-
bution of the ABCG2 efﬂux transporter. At the time of the initiation
of our study, there was only a predicted rabbit ABCG2 mRNA
sequence available (NCBI Nucleotide Database, Accession No.
XM_002716965.1, accessed 09/30/2011). Compared to the human
and rat or mice orthologues, the corresponding polypeptide
sequence showed a central deletion. This deletionwould very likely
result in a non-functional translation product. Additionally, there
was no clear information about functional activity of the ABCG2
transporter in rabbit [10,11]. In this study, we therefore cloned and
sequenced ABCG2 cDNA from rabbit placenta tissues (rbABCG2).
Moreover, we generated MDCKII cells stably expressing rbABCG2.
Using this cell line, we investigated the functional rbABCG2 activity
and compared its substrate speciﬁcity with that of the human
ABCG2 transporter.
2. Materials and methods
2.1. Reagents
Hoechst H33342 was from AppliChem (Darmstadt, Germany),
Ko143, nitrofurantoin (NF), methotrexate (amethopterin, MTX)
from SigmaeAldrich (Deisenhofen, Germany), cimetidine and PhIP
from Santa Cruz Biotechnology (Heidelberg, Germany) and dano-
ﬂoxacin mesylate (DFM) from Dr. Ehrenstorfer Inc. (Augsburg,
Germany). All chemicals were purchased at analytical grade. Oli-
gonucleotides were synthesized by Euroﬁns MWG Operon (Ebers-
berg, Germany). The following antibodies were used: monoclonal
anti-ABCG2 antibody (BXP-53) (Santa Cruz Biotechnology), mono-
clonal anti-b-actin antibody (SigmaeAldrich), alkaline phosphatase
(AP)-conjugated antibodies goat anti-rat IgG (Santa Cruz Biotech-
nology) and AP-goat anti-mouse IgG (Promega, Mannheim,
Germany).
2.2. Cell culture
MadineDarby canine kidney II cells stably transfected with
human ABCG2 (MDCKII-hABCG2) were kindly provided by Dr.
Alfred Schinkel (The Netherlands Cancer Institute, Amsterdam, the
Netherlands) and maintained as previously described [12].
2.3. Synthesis and cloning of cDNA
Total RNA was prepared from frozen placenta tissue of two
Chinchilla rabbits obtained on gestational day 28 by caesarean
section using the RNeasy Mini system (Qiagen, Hilden, Germany).
Reverse transcription into cDNA was performed with OmniscriptRT-Kit (Qiagen). The rbABCG2 cDNAs were ampliﬁed using 10 pmol
of the primer combinations shown in Table 1 and the Advanta-
ge2PCR Kit (Clontech, Heidelberg, Germany) with 40 cycles of
30 s at 95 C, 30 s at 60 C and 3 min at 68 C. PCR products were
either cloned directly into pCR XL-TOPO using the TOPO XL PCR
Cloning Kit (Invitrogen) or following isolation from the agarose gel
(SeaKern GTG Agarose, Lonza, Basel, Switzerland) with the QIA-
quick GelExtraction kit (Qiagen) into pCR4-TOPO using the TOPO TA
Cloning Kit (Invitrogen, Thermo Fisher Scientiﬁc, Waltham, MA).
Chemically competent Escherichia coli TOP10 (Invitrogen) were
transformed with the ligation products and plasmid DNA was iso-
lated from overnight cultures of kanamycin (50 mg/ml) resistant
clones using the QIAprep Spin Miniprep kit (Qiagen). Positive
plasmid DNA containing the ampliﬁed fragments was assessed by
agarose gel electrophoresis following treatment with EcoRI and by
sequencing (performed by Qiagen or SeqLab, G€ottingen, Germany).
One clone representing the consensus sequencewas subcloned into
the mammalian expression vector pIRESneo3 (Clontech) and the
resulting nucleotide sequence of prbABCG2-IRESneo3 was
conﬁrmed by sequencing.
2.4. Sequence analysis
Obtained sequences were analyzed using Applied Biosystems
Sequence Scanner v1.0. Primer design, sequence assembly and
multiple and pairwise alignment was carried out based on the
ClustalW algorithm or the Jotun Hein method, respectively, using
DNAStar (DNASTAR Inc., Madison, WI). Sequence homology
searches were performed using the BLAST algorithm on the genetic
sequence database at the National Center for Biotechnology Infor-
mation (NCBI, Bethesda, MD). Protein topology predictions were
performed with TM-Pred (www.ch.embnet.org), PSORTII (http://
psort.hgc.jp/), OCTOPUS (octupus.cbr.su.se) and the Split 4.0
Membrane Protein Secondary Structure Prediction Server (http://
split4.pmfst.hr/split/4/).
2.5. Generation of MDCKII cells stably expressing rbABCG2
MDCKII cells were transfected with 2 mg of prbABCG2-IRESneo3
using Effectene Transfection Kit (Qiagen) according to the manu-
facturer's instructions. Resistant clones were selected with
1200 mg/ml G418 (SigmaeAldrich) for 21 d and analyzed for ABCG2
expression as previously delineated [12]. Total RNA was prepared
from 3  106 MDCKII-rbABCG2 cells and cDNA was synthesized as
recently described [13]. PCR was carried out with 1 ml cDNA, Dream
Taq PCR-Mastermix (Thermo Scientiﬁc, Waltham, MA) and 10 pmol
of primers (sense: 50-ATCAGCTCCGTTGGATCATCAGG CG-30, anti-
sense: 50-AAGCGTGGCCACGGACACTACACTC-30). PCR was per-
formed over 30 cycles of 30 s at 95 C, 30 s at 66 C and 45 s at 72 C.
2.6. Pre-treatment of MDCKII-rbABCG2, MDCKII-hABCG2 or
MDCKII-WT cells
Cells were seeded in 96-well culture plates (8  103) and
incubated for 4 h with NF (8; 80 mM), MTX (5; 50 mM), cimetidine
(12; 120 mM), DFM (3; 30 mM) or with established PhIP concen-
trations (4; 40 mM, [6]). Selected drug concentrations reﬂected the
maximum human therapeutic plasma concentration (cmax) and the
10-fold cmax serum levels [14,15]. Vehicle concentrations were
generally 0.1%.
2.7. Cell proliferation assay
Cytotoxicity was evaluated using the WST-1 (4-[3-(4-
iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene
Table 1
Primer pairs successfully used for ampliﬁcation of rbABCG2 cDNA sequences.
No. Oligonucleotide sequences, forward/reverse primer product length (bp)
3 TTCTCCCACAGAAAGGCAGAAAC/GCTCCTTTTTAATATTAGGACAACTCAA 2047
4 AACTTACAGTTGTTTTTCTCCCACAGA/ACAACTCAAGGTAAATTAAAGGGGAATT 2043
6 CCCCCACAGAAAGGCAGAAA/TAGGACAACTCAAGGTAAAT 2030
S. Halwachs et al. / Placenta 38 (2016) 8e1510disulfonate) assay (Roche Applied Science, Mannheim, Germany) as
delineated previously [16]. IC50 values were deﬁned as the sub-
stance concentration reducing the absorbance by 50% and were
determined by non-linear regression analysis using Prism 5.04
(GraphPad Software Inc., San Diego, CA).2.8. Hoechst H33342 accumulation assays
MDCKII-rbABCG2, MDCKII-hABCG2 or MDCKII-WT cells were
seeded into 96-well cell culture plates (8  103). Cells were incu-
bated with H33342 (10 mM) for 5, 20 or 40 min in the presence or
absence of Ko143 (5 mM) or verapamil (50 mM). To identify potential
rbABCG2 interacting xenobiotics, cells were pre-treated with
selected substances as described in Section 2.6. Then, H33342
(10 mM) accumulation was determined for 40 min in the presence
or absence of the test substances. Cell protein was measured using
the bicinchoninic acid (BCA) assay (Pierce, Thermo Fisher Scientiﬁc,
Waltham, MA). Generally, the intracellular H33342 accumulation
was reported as relative ﬂuorescence units (RFU) per mg protein in
relation to untreated controls. The speciﬁc efﬂux activity of
rbABCG2 or hABCG2 was deﬁned as the ratio of H33342 levels in
MDCKII-rbABCG2 or MDCKII-hABCG2 cells compared to that in
MDCKII-WT cells.2.9. SDS-PAGE and Western blot analysis
Expression of ABCG2 in MDCKII-rbABCG2 or MDCKII-WT cells
was determined as previously described [12] with slight modiﬁ-
cations. In brief, nitrocellulose membranes were probed with pri-
mary ABCG2 MAb BXP-53 (1:100) or anti-b-actin MAb (1:7500)
followed by AP-conjugated goat anti-rat IgG for ABCG2 (1:5000) or
AP-conjugated goat anti-mouse IgG (1:7000) for b-actin.2.10. Statistics
Data was analyzed with Microsoft Excel software (Ofﬁce 2010).
Outliers in respective test series were eliminated with a G-test.
Differences between mean values of H33342 accumulation in
MDCKII-rbABCG2 or MDCKII-hABCG2 cells were evaluated by one-
way ANOVA followed by Fisher LSD post hoc testing using Sigma-
Plot 10 (Systat Software Inc.). Differences between mean values of
all other experimental test series were assessed by two-way
ANOVA and the Fisher LSD post hoc test. A p-value of <0.05 was
considered as statistically signiﬁcant.3. Results
3.1. cDNA cloning and sequencing
A consensus sequence of 2043 nucleotides (nt) was constructed
from four cDNA clones obtained from two different placentas. In all
eight cases, deviations from the consensus were limited to one of
the four clones, allowing for an unequivocal analysis. An open
reading frame of 1971 nt was identiﬁed within the sequence
(Supplementary Figure 1A).3.2. Predicted peptide structure of rbABCG2
Translation of the coding sequence predicts a polypeptide con-
sisting of 656 amino acids (aa) and a molecular weight of 73 kDa
(Supplementary Figure 1B). We compared this sequence with
known or predicted ABCG2 protein sequences from other species
including humans and other primates, laboratory and farm animals
as well as Xenopus laevis. Sequence identity was highest (86.1 e
86.5%) with the ABCG2 peptide sequence from man, pongo and
rhesusmonkey, followed bymousewith 85.3% and other laboratory
and farm animals with 84 e 84.4% (Table 2). Xenopus laevis ABCG2
exhibited a substantial lower sequence similarity (68.0%).
The rbABCG2 was predicted to contain six transmembrane do-
mains (TMDs) with both an intracellular N-terminus and C-termi-
nus. The localization of the TMDs was assigned to the following
regions of the aa sequence: 394e417, 428e452, 467e501, 505e531,
534e559 and 627e652 (Fig. 1). In the rbABCG2 peptide sequence
we further localized structural motifs known to be essential for
functional ABCG2 efﬂux activity. These Walker A, B and C motifs
were found at aa 80e87, 206e211 and 186e190 in rbABCG2,
respectively (Fig. 1). The Walker A and B motifs were identical to
those in human, mouse and rat with the sequences GPTGGGKS and
ILFEDE. Similar to human, the sequence of the Walker C motif in
rabbits was VSGGE. In rat and mouse the Walker C motif is ISGGE.3.3. Generation of MDCKII cells stably expressing rbABCG2
In order to characterize rabbit placental ABCG2 transport ac-
tivity, the abcg2 gene cloned from placenta tissues of chinchilla
rabbits was stably transfected in the MDCKII cell line. MCDKII-
rbABCG2 clones were selected according to their transport activ-
ity (not shown) and ABCG2 expression. ABCG2 mRNAwas detected
in MDCKII-rbABCG2 cells while no signiﬁcant transporter mRNA
levels were found in the parental MDCKII cell line (MDCKII-WT)
(Fig. 2A). In addition, Western blotting showed a pronounced band
for the ABCG2 protein migrating at a molecular weight of around
80 kDa in rbABCG2-expressing MDCKII cells (Fig. 2B). In contrast,
ABCG2 protein was not expressed in MDCKII-WT cells. Expression
of b-actin usually served as a loading control (Fig. 2).3.4. Detection of functional rbABCG2 efﬂux activity
Functional rbABCG2 activity was investigated with the Hoechst
H33342 assay [17]. To determine the involvement of ABCG2 in
cellular H33342 dye extrusion, substrate accumulationwas initially
measured in the presence or absence of the speciﬁc ABCG2 inhib-
itor Ko143 [18]. As illustrated in Fig. 3, intracellular H33342 levels
were signiﬁcantly reduced by around two thirds in MDCKII-
rbABCG2 compared to MDCKII-WT cells. In MDCK-rbABCG2 cells,
Ko143 caused a signiﬁcant increase in H33342 levels by on average
threefold indicating inhibition of rbABCG2-mediated H33342
cellular excretion (Fig. 3). In MDCKII-WT cells, Ko143 caused no
signiﬁcant alteration in H33342 levels (Fig. 3).
Table 2
Amino acid sequence for ABCG2 from rabbit, humans, other primates, laboratory and farm animals. Recent sequence information for rabbit was from this study or from NCBI
Genbank entries for all other species (Genbank reference numbers are provided in brackets). Alignment was performed using the DNAStar software and the Clustal W al-
gorithm. Results are expressed as percentage identity.
1 2 3 4 5 6 7 8 9 10
1 e rabbit
2 86.4 e human (NM_004827.2)
3 86.1 98.1 e pongo (XM_002814957.2)
4 86.5 96.8 97.1 e rhesus monkey (NM_001032919.1)
5 85.3 82.1 81.7 82.7 e mouse (NM_011920.3)
6 84.4 81.5 81.6 82.2 92.8 e Rat (NM_181381.2)
7 84.1 82.9 82.9 83.5 81.5 80.6 e dog (NM_001048021.1)
8 84.3 84.6 84.1 84.4 80.1 79.7 86.5 e cattle (NM_001037478.3)
9 84.1 85.6 85.4 85.5 80.6 80.1 86.9 96.7 e goat (NM_001285707.1)
10 84.0 85.6 85.4 85.5 80.3 79.8 86.7 96.4 99.4 e sheep (NM_001078657.1)
11 68.0 68.1 67.7 68.7 66.6 66.4 64.3 65.2 66.0 66.2 Xenopus laevis (NM_001097672.1)
Fig. 1. Prediction of the rbABCG2 peptide structure and important structural motifs. Identiﬁcation of the open reading frame from the consensus cDNA sequence of ABCG2 from
rabbit placenta, translation and localization of Walker motifs was performed using the DNAStar software package. The two-dimensional topology of the resulting polypeptide was
predicted using TM-Pred, PSORTII, OCTOPUS and Split 4.0.
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rbABCG2 or hABCG2-transduced MDCKII cells
To compare functional efﬂux activity of rbABCG2 with the hu-
man ABCG2 (hABCG2) transporter, we measured the time-
dependent H33342 accumulation in MDCKII-rbABCG2 and
MDCKII-hABCG2 cells. In both cell lines, we observed an initial
uptake phase of H33342 within the ﬁrst 20 min followed by a
plateau phase with steady state substrate levels. Incubation with
the ABCG2 inhibitor Ko143 resulted in a signiﬁcant increase in
cellular H33342 levels by approximately 3.5-fold in MDCK-
rbABCG2 (Fig. 4A) and around tenfold in MDCKII-hABCG2 cells
(Fig. 4B) after 40 min. In both cell lines, the P-glycoprotein (P-gp)
inhibitor verapamil caused no substantial alteration in the H33342
accumulation (Fig. 4).3.6. Effect of hABCG2 substrates on H33342 accumulation in
MDCKII-rbABCG2 or MDCKII-hABCG2 cells
In order to compare the substrate speciﬁcity of the rbABCG2
clone with hABCG2, we examined the effect of the established
hABCG2 substrates PhIP [6], NF [5], DFM [19], MTX [4] and cimet-
idine [20] on ABCG2-mediated H33342 efﬂux in MDCKII-rbABCG2
or MDCKII-hABCG2 cells. Potential substrates will interact with
the ABCG2 transporter and therefore can be identiﬁed in the
Hoechst assay through their inhibition of cellular H33342 excretion[17]. This inhibitory effect manifests in elevated intracellular
H33342 levels in MDCKII-rbABCG2 or MDCKII-hABCG2 compared
to untreated control cells. Besides, unspeciﬁc substrate accumula-
tion was taken into account in all experiments through normali-
zation to the corresponding H33342 accumulation in MDCKII-WT
cells.
Before initiation of transport experiments, we determined
short-term cytotoxicity (4 h) of the test substances in MDCKII
cultures by theWST-1 assay. An IC50-value of ~918 mMwas obtained
for NF. The highest NF concentration without a measurable effect
on cell viability was 400 mM (not shown). Cell viability remained
>50% after incubation with the highest applied concentration of
PhIP (400 mM), DFM (300 mM), MTX (500 mM) or cimetidine
(2400 mM) (not shown). Hence, we could not obtain an IC50-value
for these substances.
As shown in Fig. 5A, the hABCG2 model substrate PhIP caused a
dose-dependent signiﬁcant inhibition of H33342 excretion in
rbABCG2 and hABCG2 clones, which was more pronounced at
40 mM PhIP in hABCG2-compared to rbABCG2-expressing MDCKII
cells. One- and tenfold NF plasma concentrations signiﬁcantly
blocked rbABCG2 as well as hABCG2-mediated cellular H33342
efﬂux (Fig. 5B). After incubation with NF serum levels, intracellular
H33342 levels corresponded to almost two-times (MDCKII-
rbABCG2) and about 2.5-fold (MDCKII-hABCG2) the untreated
control level (Fig. 5B). The ﬂuoroquinolone antibiotic DFM caused a
signiﬁcant dose-dependent inhibition of ABCG2-mediated H33342
Fig. 2. Expression of rbABCG2 in MDCKII cells. (A) Total RNA isolated from 3 x 106 cells
was used for RT-PCR analysis of rbABCG2-transduced or MDCKII-WT cells as described
in the Material and Methods Section 2.7. (B) Western blot analysis of the MDCKII-
rbABCG2 and MDCKII-WT cell line was performed with 30 mg of total protein sepa-
rated on a 7.5% polyacrylamide gel. ABCG2 was detected using monoclonal antibody
BXP-53 and is apparent at ~72e80 kDa (/). b-actin was used as a loading control and
is apparent at ~45 kDa (/). The results shown are representative of two independent
experiments.
Fig. 3. Functional efﬂux activity of rabbit placental ABCG2. MDCKII-rbABCG2 or -WT
cells were incubated with 10 mMHoechst H33342 in presence or absence of the speciﬁc
ABCG2 inhibitor Ko143 (5 mM) for 20 min. Efﬂux activity of rbABCG2 was measured
ﬂuorometrically as the time-dependent reduction of intracellular H33342 accumula-
tion as delineated in the Material and Methods section. MDCKII-WT cells lacking
ABCG2 expression served as a control. Finally, H33342 accumulation was expressed as
RFU per mg protein. The results represent the mean ± SEM (*p < 0.001 signiﬁcance to
MDCKII-WT control cells, #p < 0.001 to untreated MDCKII-rbABCG2 cells, two-way
ANOVA, Fisher LSD post hoc test, n ¼ 6).
Fig. 4. Impact of Ko143 and verapamil on cellular Hoechst H33342 excretion in
MDCKII-rbABCG2 or -hABCG2 cells. Cells were incubated with H33342 (10 mM) for 5,
20 or 40 min in the presence or absence of the ABCG2 inhibitor Ko143 or the Pg-p
inhibitor verapamil as delineated in the Material and Methods Section 2.8. ABCG2
efﬂux activity was determined as described in the legend of Fig. 3. Values are
mean ± SEM (**p < 0.01, ***p < 0.001 signiﬁcance to untreated control cells, one-way
ANOVA, Fisher LSD post hoc test, n ¼ 12).
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control, DFM plasma concentrations blocked the H33342 efﬂux
resulting in ~1.7-fold elevated substrate levels in MDCKII-rbABCG2
cells and by on average 1.5-fold in the hABCG2 clone. As illustrated
in Fig. 5D, MTX signiﬁcantly inhibited the H33342 efﬂux in both
ABCG2 clones with a dose-dependent effect only observed with
rbABCG2. In relation to untreated control cells, treatment with one-fold MTX serum levels resulted in a ~1.6-fold and ~2.2-fold increase
in H33342 levels in MDCKII-rbABCG2 and -hABCG2 cells, respec-
tively (Fig. 5D). Both concentrations of cimetidine signiﬁcantly
blocked H33342 efﬂux in rbABCG2-expressing cells resulting in a
1.5-fold increase of H33342 control levels (Fig. 5E). In the MDCKII-
hABCG2 cell line, we observed a dose-dependent inhibition of
H33342 excretion manifesting in a doubling of cellular H33342
levels with cimetidine plasma concentrations. Generally, only NF
plasma concentrations caused a signiﬁcant stronger inhibition of
H33342 efﬂux in the hABCG2 compared to the rbABCG2 clone
(Fig. 5B). Serum levels of all other tested drugs or 4 mM PhIP had a
similar inhibitory effect on cellular H33342 excretion in both
ABCG2 clones (Fig. 5).
4. Discussion
In humans, the ABCG2 efﬂux transporter substantially contrib-
utes to the fetoprotective placental barrier function. Due to the
similar morphology of the human and the rabbit placenta [8],
developmental toxicity studies of chemicals are preferably per-
formed in rabbit [7].
Fig. 5. Impact of PhIP and selected drugs on Hoechst H33342 accumulation in MDCKII-rbABCG2 or hABCG2 cells. ABCG2 clones were pre-treated (4 h) with one- and tenfold
therapeutic plasma concentrations of selected drugs or the toxin PhIP. Subsequently, cells were incubated for 40 minwith H33342 (10 mM) in presence or absence of PhIP (A), NF (B),
DFM (C), MTX (D) or cimetidine (E). ABCG2 efﬂux activity was assessed as delineated in the legend of Fig. 3. Data represent the mean ± SEM (*p < 0.05 signiﬁcance to untreated
control cells, #p < 0.05 signiﬁcance to MDCKII-hABCG2 cells, two-way ANOVA, Fisher LSD post hoc test, n ¼ 12).
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expression, we cloned the ABCG2 transporter from chinchilla rabbit
placenta tissues. The cDNA clone was referred to as rbABCG2
henceforward. The ﬁrst hypothetical rabbit ABCG2 mRNA sequence
was predicted in 2010 at the time of the initiation of our study
(GenBank accession no. XM_002716965). Pairwise alignment of
rbABCG2 with this hypothetical ABCG2 mRNA sequence shows
good agreement in the terminal regions. However, compared to the
rbABCG2, the nt 1416 to 1534 of the cDNA sequence were replaced
in the predicted mRNA by an unrelated stretch of 96 nt. Conse-
quently, on the polypeptide level, this would relate to a loss of the
amino acids (aa) 458 to 498 and probably result in a non-functional
transport protein. Recently, a new automated computational rabbit
ABCG2 mRNA sequence prediction became available (Genbank
accession no. XM_008267616). Here, pairwise alignment with
rbABCG2 showed a high degree of identity in the overlapping
cDNA/mRNA sequence, amounting to 99.6% within the predicted
ORF. Moreover, the aa sequences were identical when predicted
from the consensus rbABCG2 cDNA and this hypothetical mRNA.
Interestingly, Western blot analysis of the rbABCG2 clone produced
bands slightly higher as the predictedmolecular weight of rbABCG2
(Mr 72,912). This is in line with previous data of ruminant ABCG2
[12] and probably corresponds to the core- and fully glycosylated
carrier protein as shown previously for human ABCG2 [21]. How-
ever, previous studies indicate that the ABCG2 glycosylation status
neither signiﬁcantly effects cellular expression, protein half-live,
the trafﬁcking to the plasma membrane nor the overall functional
efﬂux activity of the ABCG2 transporter [22].
In order to examine the functional transport activity of rbABCG2
we aimed to establish a suitable cell culture model of the rabbit
placental barrier. The blood-placental barrier is generally
composed of tight-junctioned syncytiotrophoblasts with an apical
side facing thematernal blood and a basolateral side facing the fetal
fenestrated capillaries [23]. Normally, human primary cytotropho-
blasts or human choriocarcinoma BeWo, JEG-3 or JAR cells are used
as in vitro placenta models. However, none of these cells aresuggested as sufﬁciently standardized placenta barrier models
[4,24]. Therefore, we stably transduced the rbABCG2 clone in
MDCKII cells. The MDCKII cell line represents a well-established
in vitro tool for the study of ABCG2-mediated substrate transport
[17,25]. Similarly to the placenta barrier in vivo, MDCKII cells
derived from kidney tubule epithelia form polarized monolayers
with functional tight junctions [26]. Moreover, MDCK cells and
placenta tissues show a similar expression pattern of ABC multi-
drug transporters like ABCG2 [24]. Therefore, MDCKII-rbABCG2
cells overall represent an adequate in vitro tool to study ABCG2-
mediated transport of xenobiotics in rabbit placenta.
Using the H33342 accumulation assay and the speciﬁc ABCG2
inhibitor Ko143, we demonstrated functional efﬂux activity of the
ABCG2 transporter from rabbit placenta. Similarly, the speciﬁc
ABCG2-mediated transport of H33342 was shown in rabbit corneal
limbus epithelial cells [10]. The Hoechst dye is also a substrate of
the ABC efﬂux transporter P-glycoprotein (P-gp) [27]. However, the
P-gp inhibitor verapamil did not block the initial (20 min) H33342
efﬂux and had only a slight inhibitory effect on H33342 accumu-
lation in MDCKII-rbABCG2 cells for 40 min. Hence, H33342 efﬂux
can be clearly attributed to functional rbABCG2 activity. The
detection of functional rbABCG2 activity is corroborated by the
identiﬁcation of important structural features in the predicted
rbABCG2 protein including six TMDs. This is similar to all ABCG
subfamily members that are present as half-transporters [28].
Moreover, we identiﬁedWalker A and Bmotifs within the rbABCG2
peptide sequence. These motifs are highly conserved in ATP-
binding proteins and are known to be vitally required for ABC
carrier-mediated transport [28].
Due to interspecies differences, data derived in animal studies
are difﬁcult to translate directly to human. Hence, we investigated
rbABCG2 substrate speciﬁcity compared to that of the human
ABCG2 (hABCG2) transporter. Therefore, we investigated in-
teractions between selected hABCG2 substrates with rbABCG2 in
comparison to hABCG2. Using the established H33342 screening
assay [12,17], we identiﬁed the food carcinogen PhIP as a potential
S. Halwachs et al. / Placenta 38 (2016) 8e1514substrate of the ABCG2 efﬂux transporter in rabbit placenta.
Concordantly, ABCG2 was shown to decrease the PhIP
fetalematernal concentration ratio in perfused human placenta [6].
Additionally, we detected rbABCG2-drug interactions with thera-
peutic plasma concentrations of all tested drugs. Hence, our data
suggest that the drugs NF, MTX, cimetidine, and DFM are rbABCG2
substrates. Concordantly, studies in Abcg2/mice and rat perfused
placenta showed that Abcg2 signiﬁcantly limits fetal exposure with
NF and cimetidine, respectively [29,30]. Moreover, the observed
blockage of H33342 excretion by the tested compounds was com-
parable in rbABCG2-and hABCG2-expressing MDCKII-cells. Hence,
our study altogether suggests a similar drug interaction potential of
the rabbit and human ABCG2 transporter. This assumption is
corroborated by the high peptide sequence identity of rbABCG2 and
hABCG2. Interestingly, no other of the examined mammals showed
a higher sequence similarity to the primates than the rabbit.
However, the Hoechst assay represents an indirect setup and
therefore does not clearly distinguish between ABCG2 substrates
and inhibitors [17]. Our results will therefore be validated by
further transepithelial transport studies [25]. Additionally, MDCKII
cells overexpressing the ABCG2 transporter do not allow adequate
kinetic analyses. Hence, the Hoechst assay in conjunction with
ABCG2-transduced MDCKII cells overall allow the qualitative but
not the quantitative comparison of human versus rabbit ABCG2/
xenobiotic interactions. Moreover, the expression of rabbit or hu-
man ABCG2 in MDCKII cells may not reﬂect the transporter
expression in human or rabbit placenta in vivo. To the best of our
knowledge, there is no information so far on ABCG2 expression per
gram of human or rabbit placenta tissues. Further studies using
placenta tissue slices or primary placenta cells have to be per-
formed to considerate species-speciﬁc difference in ABCG2
expression levels and the evaluation of the actual level of efﬂux in
human compared to rabbit placenta.
Altogether, we ﬁrst cloned and showed functional expression of
the ABCG2 efﬂux transporter in rabbit placenta with a comparable
drug interaction potential compared to human ABCG2. This in-
cludes drugs like NF routinely used to treat urinary tract infections
in pregnancy [31] or MTX that is commonly employed in gesta-
tional trophoblastic neoplasia chemotherapy [32]. Hence, our re-
sults regarding active transport of xenobiotics in the placenta by
rabbit or human ABCG2 contribute to corroborate the usefulness of
the rabbit as an adequate reproductive model for testing the
developmental toxicity of chemicals in human. Therefore, the
MDCKII-rbABCG2 cell line may serve as a valuable in vitro tool for
mechanistic studies in the context of developmental toxicity
testing.
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